Related content

Co-expression of CXCR4 and CD133 proteins is associated with poor prognosis in stage II-III colon cancer patients

By                

Experimental and Therapeutic Medicine, Vol. 3, Iss. 6, 2012-01 ,pp. : 973-982

Spandidos Publications

Access to resources Recommend Favorite

Cell Cycle Proteins Predict Recurrence in Stage II and III Colon Cancer

By Belt Eric   Brosens Rebecca   Delis-van Diemen Pien   Bril Herman   Tijssen Marianne   Essen Dirk   Heymans Martijn   Beliën Jeroen   Stockmann Hein   Meijer Sybren   Meijer Gerrit  

Annals of Surgical Oncology, Vol. 19, Iss. 3, 2012-07 ,pp. : 682-692

Springer Publishing Company

Access to resources Recommend Favorite

Practical Outcome of Adjuvant FOLFOX4 Chemotherapy in Elderly Patients with Stage III Colon Cancer: Single-center Study in Korea

By Kim Ji-Yeon   Kim Yu Jung   Lee Keun-Wook   Lee Jong Seok   Kim Duck-Woo   Kang Sung-Bum   Lee Hye Seung   Jang Na Young   Kim Jae-Sung   Kim Jee Hyun  

Japanese Journal of Clinical Oncology, Vol. 43, Iss. 2, 2013-02 ,pp. : 132-138

Oxford University Press

Access to resources Recommend Favorite

Capecitabine: As Adjuvant Therapy in Stage III Colon Cancer

By Robins Gayle W.   Keating Gillian M.  

American Journal of Cancer, Vol. 4, Iss. 5, 2005-01 ,pp. : 315-323

Adis International

Access to resources Recommend Favorite

FOLFOX and FLOX Regimens for the Adjuvant Treatment of Resected Stage II and III Colon Cancer

By Sharif Saima   O'Connell Michael   Yothers Greg   Lopa Samia   Wolmark Norman  

Cancer Investigation, Vol. 26, Iss. 9, 2008-11 ,pp. : 956-963

Informa Healthcare

Access to resources Recommend Favorite